Katherine Goodrich - 13 Nov 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
13 Nov 2024
Net transactions value
$0
Form type
4
Filing time
15 Nov 2024, 16:37:08 UTC
Next filing
16 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +10,000 $0.000000 10,000 13 Nov 2024 Common Stock 10,000 $46.51 Direct F1
transaction TARS Restricted Stock Units Award $0 +6,700 $0.000000 6,700 13 Nov 2024 Common Stock 6,700 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shares will vest in three equal annual installments beginning on November 13, 2025, subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 The RSUs will vest in three equal annual installments on December 15th of each of 2025, 2026, and 2027, subject to the Reporting Person's continuous service.